מכפיל מחיר להכנסות עתידי: Imunon (IMNN)

Imunon, Inc. (IMNN) develops DNA vaccines to combat oncology, leveraging the success of medical trials. The absence of current sales makes the stock price dependent on research, which is illustrated by the forward P/S based on forecasts on the general GURU.Markets platform chart, where the value of 127.20 characterizes this level. The strategy is based on the TheraPlas system for patients with severe forms of tumors.

Conservative capital requires transparent forecasting of business sustainability, which is why this indicator compares current market capitalization with expected sales volume to assess the company's margin of safety. The forward P/S dynamics for Imunon, Inc. (IMNN) reflect market expectations regarding the commercialization of DNA plasmid therapy for ovarian cancer, allowing investors to evaluate the extent to which R&D risks are currently priced into the stock.